View More Recent Stories

Feb 11, 2025 11:58AM Arvinas Inc. (ARVN) PT Lowered to $82 at BMO Capital
Feb 11, 2025 07:03AM Arvinas, Inc. (ARVN) Tops Q4 EPS by 33c
Feb 3, 2025 07:23AM Arvinas Inc. (ARVN) PT Lowered to $49 at Leerink Partners
Jan 10, 2025 07:08AM Arvinas Inc. (ARVN) Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update
Jan 8, 2025 03:09PM Arvinas Inc. (ARVN) March 12.50 puts, March 22.25 calls and March 30 calls active
Dec 22, 2024 04:00AM Barclays shares outlook for Biotech in 2025, names preferred stocks
Dec 10, 2024 09:09AM Arvinas (ARVN) and Pfizer (PFE) Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
Nov 26, 2024 07:46AM BMO Capital Reiterates Outperform Rating on Arvinas Inc. (ARVN)
Nov 20, 2024 10:46AM Arvinas Inc. (ARVN) PT Lowered to $88 at BMO Capital
Nov 19, 2024 11:10AM Arvinas Inc. (ARVN) PT Lowered to $62 at Leerink Partners
Oct 31, 2024 07:54AM Arvinas Inc. (ARVN) PT Lowered to $40 at Oppenheimer
Oct 30, 2024 07:11AM Arvinas, Inc. (ARVN) Tops Q3 EPS by 16c, provides guidance
Oct 21, 2024 06:18AM Stifel Reiterates Buy Rating on Arvinas Inc. (ARVN)
Oct 1, 2024 06:47AM Wells Fargo Offers 10 High-Conviction Long/Short Ideas for Q4, Comments on tesla (TSLA): 'We see declining delivery growth'
Jul 30, 2024 09:30AM Arvinas, Inc. (ARVN) Tops Q2 EPS by 59c
Jul 22, 2024 08:31AM HOOKIPA Pharma Inc. (HOOK) Announces Leadership Changes to Intensify Focus on HB-200
Jun 24, 2024 04:37PM Arvinas Inc. (ARVN) Appoints Andrew Saik as CFO and Treasurer
Jun 17, 2024 07:00AM Arvinas Inc. (ARVN) Appoints Angela Cacace as Chief Scientific Officer, Ian Taylor as President of R&D
View More Recent Stories